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Synthesizing information on test performance metrics
such as sensitivity, specificity, predictive values and
likelihood ratios is often an important part of a system-
atic review of a medical test. Because many metrics of
test performance are of interest, the meta-analysis of
medical tests is more complex than the meta-analysis of
interventions or associations. Sometimes, a helpful way
to summarize medical test studies is to provide a
“summary point”, a summary sensitivity and a sum-
mary specificity. Other times, when the sensitivity or
specificity estimates vary widely or when the test
threshold varies, it is more helpful to synthesize data
using a “summary line” that describes how the average
sensitivity changes with the average specificity. Choos-
ing the most helpful summary is subjective, and in
some cases both summaries provide meaningful and
complementary information. Because sensitivity and
specificity are not independent across studies, the
meta-analysis of medical tests is fundamentaly a
multivariate problem, and should be addressed with
multivariate methods. More complex analyses are need-
ed if studies report results at multiple thresholds for
positive tests. At the same time, quantitative analyses
are used to explore and explain any observed dissimi-
larity (heterogeneity) in the results of the examined
studies. This can be performed in the context of proper
(multivariate) meta-regressions.
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INTRODUCTION
The series of papers in this supplement of the journal
highlights common challenges in systematic reviews of
medical tests and outlines their mitigation, as perceived by
researchers partaking in the Agency for Healthcare Research
and Quality (AHRQ) Effective Healthcare Program. Generic
by their very nature, these challenges and their discussion
apply to the larger set of systematic reviews of medical tests,
and are not specific to AHRQ’s program.
This paper focuses on choosing strategies for meta-analysis
of test “accuracy”, or more preferably, test performance.
Meta-analysis is not required for a systematic review, but
when appropriate, it should be undertaken with a dual goal:
to provide summary estimates for key quantities, and to
explore and explain any observed dissimilarity (heterogene-
ity) in the results of the examined studies.
“Summing-up” information on test performance metrics
such as sensitivity, specificity, and predictive values is rarely
the most informative part of a systematic review of a medical
test.
1–4 Key clinical questions driving the evidence synthesis
(e.g., is this test alone or in combination with a test-and-treat
strategy likely to improve decision-making and patient
outcomes?) are only indirectly related to test performance
per se. Formulating an effective evaluation approach requires
careful consideration of the context in which the test will be
used. These framing issues are addressed in other papers in
this issue of the journal.
5–7 Further, in this paper we assume
that medical test performance has been measured against a
“gold standard”, that is a reference standard that is
considered adequate in defining the presence or absence of
the condition of interest. Another paper in this supplement
discusses ways to summarize medical tests when such a
reference standard does not exist.
8
Syntheses of medical test data often focus on test perfor-
mance, and much of the attention to statistical issues relevant
to synthesizing medical test evidence focuses on summarizing
test performance data; thus their meta-analysis was chosen to
be the focus of this paper. We will assume that the decision to
perform meta-analyses of test performance data is justified
and taken, and will explore two central challenges, namely
how do we quantitatively summarize medical test perfor-
mance when: 1) the sensitivity and specificity estimates of
S56various studies do not vary widely, or 2) the sensitivity and
specificity of various studies vary over a large range.
1) Briefly, it may be helpful to use a “summary point” (a
summary sensitivity and summary specificity pair) to
obtain summary test performance when sensitivity and
specificity estimates do not vary widely across studies.
This could happen in meta-analyses where all studies have
the same explicit test positivity threshold (a threshold for
categorizing the results of testing as positive or negative)
since if studies have different explicit thresholds, the
clinical interpretation of a summary point is less obvious,
and perhaps less helpful. However, an explicit common
threshold is neither sufficient nor necessary for opting to
synthesize data with a “summary point”; a summary point
can be appropriate whenever sensitivity and specificity
estimates do not vary widely across studies.
2) When the sensitivity and specificity of various studies
vary over a large range, rather than using a “summary
point”, it may be more helpful to describe how the
average sensitivity and average specificity relate by
means of a “summary line”. This oft-encountered
situation can be secondary to explicit or implicit
variation in the threshold for a “positive” test result,
heterogeneity in populations, reference standards, or the
index tests, study design, chance, or bias.
Of note, in many applications it may be informative to
present syntheses in both ways, as they convey comple-
mentary information.
Deciding whether a “summary point” or a “summary line” is
more helpful as a synthesis is subjective, and no hard-and-fast
rules exist. We briefly outline common approaches for meta-
analyzing medical tests, and discuss principles for choosing
between them. However, a detailed presentation of methods or
their practical application is outside the scope of this work. In
addition, it is expected that readers are versed in clinical
research methodology, and familiar with methodological
issues pertinent to the study of medical tests. We also assume
familiarity with the common measures of medical test
performance (reviewed in the Appendix, and in excellent
introductory papers).
9 For example, we do not review
challenges posed by methodological or reporting shortcomings
of test performance studies.
10 The Standards for Reporting of
Diagnostic accuracy (STARD) initiative published a 25-item
checklist that aims to improve reporting of medical tests
studies.
10 We refer readers to other papers in this issue
11 and to
several methodological and empirical explorations of bias and
heterogeneity in medical test studies.
12–14
Nonindependence ofsensitivityand specificity
across studies and why it matters
for meta-analysis
In a typical meta-analysis of test performance, we have
estimates of sensitivity and specificity for each study, and
seek to provide a meaningful summary across all studies.
Within each study sensitivity and specificity are independent,
because they are estimated from different patients (sensitivity
from those with the condition of interest, and specificity from
those without). According to the prevailing reasoning, across
studies sensitivity and specificity are likely negatively
correlated: as one estimate increases the other is expected to
decrease. This is perhaps more obvious when studies have
different explicit thresholds for “positive” tests (and thus the
term “threshold effect” has been used to describe this negative
correlation). For example, the D-dimer concentration thresh-
old for diagnosing an acute coronary event can vary from
approximately 200 to over 600 ng/mL.
15 It is expected that
higher thresholds would correspond to generally lower
sensitivity but higher specificity, and the opposite for lower
thresholds (though in this example it is not clearly evident;
see Fig. 1a). A similar rationale can be invoked to explain
between-study variability for tests with more implicit or
suggestive thresholds, such as imaging or histological tests.
Negativecorrelationbetweensensitivityandspecificityacross
studies may be expected for reasons unrelated to thresholds for
positive tests. For example, in a meta-analysis evaluating the
ability of serial creatine kinase-MB (CK-MB) measurements to
diagnose acute cardiac ischemia in the emergency depart-
ment,
16, 17 the time interval from the onset of symptoms to
serial CK-MB measurements (rather than the actual threshold
for CK-MB) could explain the relationship between sensitivity
and specificity across studies. The larger the time interval, the
more CK-MB is released into the bloodstream, affecting the
estimated sensitivity and specificity. Unfortunately, the term
“threshold effect” is often used rather loosely to describe the
relationship between sensitivity and specificity across studies,
even when, strictly speaking, there is no direct evidence of
variability in study thresholds for positive tests.
Because of the above, the current thinking is that in general,
the study estimates of sensitivity and specificity do not vary
independently, but jointly, and likely with a negative correla-
tion. Summarizing the two correlated quantities is a multivar-
iate problem, and multivariate methods should be used to
address it, as they are more theoretically motivated.
18, 19 At the
same time there are situations when a multivariate approach is
not practically different from separate univariate analyses. We
will expand on some of these issues.
PRINCIPLES FOR ADDRESSING THE CHALLENGES
To motivate our suggestions on meta-analyses of medical
tests, we invoke two general principles
& Principle 1: Favor the most informative way to
summarize the data. Here we refer mainly to choosing
between a summary point and a summary line, or both.
& Principle 2: Explore the variability in study results with
graphs and suitable analyses, rather than relying
exclusively on “grand means”.
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Which metrics to meta-analyze
For each study, the estimates of sensitivity, specificity,
predicitive values, likelihood ratios, and prevalence are
related through simple formulas (Appendix). However, if
one performed a meta-analysis for each of these metrics, the
summaries across all studies will generally be inconsistent:
the formulas would not be satisfied for the summary
estimates. To avoid this, we propose to obtain summaries
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Figure 1. Typical data on the performance of a medical test (D-dimers for venous thromboembolism). Eleven studies on ELISA-based D-
dimer assays for the diagnosis of venous thromboembolism.
15 The top panel (a) depicts studies as markers, labeled by author names and
thresholds for a positive test (in ng/mL). Studies listed on the left lightly shaded area have a positive likelihood ratio of at least 10. Studies
listed on the top lightly shaded area have a negative likelihood ratio of at most 0.1. Studies listed at the intersection of the gray areas (darker
gray polygon) have both a positive likelihood ratio of at least 10 and a negative likelihood ratio of 0.1 or less. The second panel (b) shows
‘paired’ forest plots in ascending order of sensitivity (left) along with with the corresponding specificity (right). Note how sensitivity
increases with decreasing specificity, which could be explained by a “threshold effect”. The third panel (c) shows the respective negative and
positive likelihood ratios.
S58 Trikalinos et al.: Meta-analysis of tests when there is a “gold standard” JGIMfor sensitivities and specificities via meta-analysis, and to
back-calculate the overall predictive values or likelihood
ratios from the formulas in the Appendix, for a range of
plausible prevalences. Figure 2 illustrates this strategy for a
meta-analysis of K studies. We explain the rationale below.
Why it does make sense to directly meta-analyze sensitivity
and specificity. Summarizing studies with respect to
sensitivity and specificity aligns well with our
understanding of the effect of positivity thresholds for
diagnostic tests. Further, sensitivity and specificity are often
considered independent of the prevalence of the condition
under study (though this is an oversimplification that merits
deeper discussion).
20 The summary sensitivity and
specificity obtained by a direct meta-analysis will always
be between zero and one. Because these two metrics do not
have as intuitive an interpretation as likelihood ratios or
predictive values,
9 we can use formulas in the Appendix to
back-calculate “summary” (overall) predictive values and
likelihood ratios that correspond to the summary sensitivity
and specificity for a range of plausible prevalence values.
Why it does not make sense to directly meta-analyze
positive and negative predictive values or prevalence.
Predictive values are dependent on prevalence estimates.
Because prevalence is often wide ranging, and because
many medical test studies have a case-control design (where
prevalence cannot be estimated), it is rarely meaningful to
directly combine these across studies. Instead, predictive
values can be calculated as mentioned above from the
summary sensitivity and specificity for a range of plausible
prevalence values.
Why directly meta-analyzing likelihood ratios could be
problematic. Positive and negative likelihood ratios could
also be combined in the absence of threshold variation, and
in fact, many authors give explicit guidance to that effect.
21
However, this practice does not guarantee that the summary
positive and negative likelihood ratios are “internally
consistent”. Specifically, it is possible to get summary
likelihood ratios that correspond to impossible “summary”
sensitivities or specificities (outside the zero to one
interval).
22 Back-calculating the “summary” likelihood
ratios from summary sensitivities and specificities avoids
this complication. Nevertheless, these aberrant cases are not
common,
23 and calculations of summary likelihood ratios
by directly meta-analyzing them or from back calculation of
the summary sensitivity and specificity rarely results in
different conclusions.
23
Directly meta-analyzing diagnostic odds ratios. The
synthesis of diagnostic odds ratios is straightforward and
follows standard meta-analysis methods.
24, 25 The
diagnostic odds ratio is closely linked to sensitivity,
specificity, and likelihood ratios, and it can be easily
included in meta-regression models to explore the impact
of explanatory variables on between-study heterogeneity.
Apart from challenges in interpreting diagnostic odds ratios,
a disadvantage is that it is impossible to weight the true
positive and false positive rates separately.
Figure 2. Obtaining summary (overall) metrics for medical test performance. PLR/NLR = positive (negative) likelihood ratio; PPV/NPV =
positive (negative) predictive value; Prev = prevalence; Se = Sensitivity; Sp = specificity. The herein recommended approach is to perform a
meta-analysis for sensitivity and specificity across the K studies, and then use the summary sensitivity and specificity (Se+ and Sp+; a row of
two boxes after the horizontal black line) to back-calculate “overall” values for the other metrics (second row of boxes after the horizontal
black line). In most cases it is not meaningful to synthesize prevalences (see text).
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methods
Over several decades many methods have been used for
meta-analyzing medical test performance data. Based on
the above considerations, methods should be motivated
by (a) respecting the multivariate nature of test perfor-
mance metrics (i.e., sensitivity and specificity); (b)
allowing for the nonindependence between sensitivity
and specificity across studies (“threshold effect”)a n d( c )
allowing for between-study heterogeneity. Table 1 lists
commonly used methods for meta-analysis of medical
tests. The most theoretically motivated meta-analysis
approaches are based on multivariate methods(hierarchical
modeling).
We will focus on the case where each study reports a
single pair of sensitivity and specificity at a given
threshold (although thresholds can differ across studies).
Another, more complex situation arises when multiple
sensitivity and specificity pairs (at different thresholds) are
reported in each study. Statistical models for the latter case
exist, but there is less empirical evidence on their use.
These will be described briefly, as a special case.
Preferred methods for obtaining a “summary
point” (summary sensitivity and specificity):
two families of hierarchical models
When a “summary point” is deemed a helpful summary of a
collection of studies, one should ideally perform a multivar-
iate meta-analysis of sensitivity and specificity, i.e., a joint
analysis of both quantities, rather than separate univariate
meta-analyses. This is not only theoretically motivated,
26–28
but also corroborated by simulation analyses.
1, 27, 29
Multivariate meta-analyses require advanced hierarchical
modeling. We can group the commonly used hierarchical
models in two families: The so called “bivariate model”
26 and
the “hierarchical summary ROC” (HSROC) model.
30 Both
use two levels to model the statistical distributions of data. At
the first level, they model the counts of the 2×2 table within
each study, which accounts for within-study variability. At the
second level, they model the between-study variability
(heterogeneity), allowing for the theoretically expected
nonindependence of sensitivity and specificity across studies.
The two families differ in their parameterization at this second
level: the bivariate model uses parameters that are trans-
formations of the average sensitivity and specificity—while
Table 1. Commonly Used Methods for Meta-Analysis of Medical Test Performance
Method Description or comment Does it have desired characteristics?
Summary point
Independent meta-analysis of
sensitivity and specificity
Separate meta-analyses per metric Ignores correlation between sensitivity and
specificity
Within-study variability preferably modeled by the
binomial distribution.
44 Underestimates summary sensitivity and
specificity and incorrect confidence intervals
26
Joint (multivariate) meta-analysis of
sensitivity and specificity based on
hierarchical modeling
Based on multivariate (joint) modeling of sensitivity
and specificity.
The generally preferred method
Two families of models
26, 30 (see text), equivalent
when there are no covariates
18
Modeling preferably using binomial likelihood rather
than normal approximations
30, 37, 45, 46
Summary line
Moses and Littenberg model Summary line based on a simple regression of the
difference of logit-transformed true and false
positive rates versus their average.
32–34
Ignores unexplained variation between-studies
(fixed effects)
Does not account for correlation between
sensitivity and specificity
Does not account for variability in the
independent variable
Inability to weight studies optimally—yields
wrong inferences when covariates are used
Random intercept augmentation of
the Moses-Littenberg model
Regression of the difference of logit-transformed true
and false positive rates versus their average with
random effects to allow for variability across
studies
35, 36
Does not account for correlation between
sensitivity and specificity
Does not account for variability in the
independent variable
Summary ROC based on hierarchical
modeling
Same as for multivariate meta-analysis to obtain a
summary point—hierarchical modeling
26, 30 Most theoretically motivated method
Many ways to obtain a (hierarchical) summary ROC : Rutter-Gatsonis HSROC recommended in the
Cochrane handbook,
47 as it is the method
with which there is most experience
Rutter-Gatsonis (most common)
30
Several alternative curves
37, 38
S60 Trikalinos et al.: Meta-analysis of tests when there is a “gold standard” JGIMthe HSROC model uses a scale parameter and an accuracy
parameter, which are functions of sensitivity and specificity,
and define an underlying hierarchical summary ROC curve.
Inthe absence of covariates,thetwofamilies of hierarchical
models are mathematically equivalent; one can use simple
formulas to relate the fitted parameters of the bivariate model
to the HSROC model and vice versa, rendering choices
between the two approaches moot.
18 The importance of
choosing between the two families becomes evident in meta-
regression analyses, when covariates are used to explore
between-study heterogeneity. The differences in design and
conduct of the included diagnostic accuracy studies may
affect the choice of the model.
18 For example, “spectrum
effects,” where the subjects included in a study are not
representative of the patients who will receive the test in
practice,
31 “might be expected to impact test accuracy rather
than the threshold, and might therefore be most appropriately
investigated using the HSROC approach. Conversely, be-
tween-study variation in disease severity will (likely) affect
sensitivity but not specificity, leading to a preference for the
bivariate approach.”
18 When there are covariates in the
model, the HSROC model allows direct evaluation of the
difference in accuracy or threshold parameters or both, which
affect the degree of asymmetry of the SROC curve, and how
much higher it is from the diagonal (the line of no diagnostic
information).
18 Bivariate models, on the other hand, allow
for direct evaluation of covariates on sensitivity or specificity
or both. Systematic reviewers are encouraged to look at study
characteristics and think through how study characteristics
could affect the diagnostic accuracy, which in turn might
affect the choice of the meta-regression model.
Preferred methods for obtaining a “summary
line”
When a summary line is deemed more helpful in summarizing
the available studies, we recommend summary lines obtained
from hierarchical modeling, instead of several simpler
approaches (Table 1).
32–36 As mentioned above, when there
are no covariates, the parameters of hierarchical summary
lines can be calculated from the parameters of the bivariate
random effects models using formulas.
18, 30, 37 In fact, a whole
range of HSROC lines can be constructed using parameters
from the fitted bivariate model;
37, 38 one proposed by Rutter
and Gatsonis
30 is an example. The various HSROC curves
represent alternative characterizations of the bivariate distribu-
tion of sensitivity and specificity, and can thus have different
shapes. Briefly, apart from the commonly used Rutter-
Gatsonis HSROC curve, alternative curves include those
obtained from a regression of logit-transformed true positive
rate on logit-transformed false positive rate; logit false positive
rate on logit true positive rate; or the major axis regression
between logit true and false positive rates.
37, 38
When the estimated correlation between sensitivity and
specificity is positive (as opposed to the typical negative
correlation) the latter three alternative models can generate
curves that follow a downward slope from left to right. This is
not as rare as once thought
37– a downward slope (from left to
right) was observed in approximately one out of three meta-
analyses in a large empirical exploration of 308 meta-analyses
(report under review, Tufts Evidence-based Practice Center).
Chappell et al. argued that in meta-analyses with evidence of
positive estimated correlation between sensitivity and speci-
ficity (e.g., based on the correlation estimate and confidence
interval or its posterior distribution) it is meaningless to use an
H S R O Cl i n et os u m m a r i z et h es t u d i e s ,
38 as a “threshold
effect” explanation is not possible. Yet, even if the estimated
correlation between sensitivity and specificity is positive (i.e.,
not in the “expected” direction), an HSROC still represents
how the summary sensitivity changes with the summary
specificity. The difference is that the explanation for the
pattern of the studies cannot involve a “threshold effect”;
rather, it is likely that an important covariate has not been
included in the analysis (see the proposed algorithm below).
38
A special case: joint analysis of sensitivity
and specificity when studies report multiple
thresholds
It is not uncommon for some studies to report multiple
sensitivity and specificity pairs at several thresholds for
positive tests. One option is to decide on a single threshold
from each study and apply the aforementioned methods. To
some extent, the setting in which the test is used can guide
the selection of the threshold. For example, in some cases,
the threshold which gives the highest sensitivity may be
appropriate in medical tests to rule-out disease. Another
option is to use all available thresholds per study.S p e c i f i -
cally, Dukic and Gatsonis extended the HSROC model to
analyze sensitivity and specificity data reported at more than
one threshold.
39 This model represents as extension of the
HSROC model discussed above. Further, if each study
reports enough data on sensitivity and specificity to construct
a ROC curve, Kester and Buntinx
40 proposed a little-used
method to combine whole ROC curves.
Both models are theoretically motivated. The Dukic and
Gatsonis model is more elaborate and more technical in its
implementation than the Kester and Buntinx variant. There is
no empirical evidence on the performance of either model in a
large number of applied examples. Therefore, we refrain from
providing a strong recommendation to always perform such
analyses. Systematic reviewers are mildly encouraged to
perform explorations, including analyses with these models.
Should they opt to do so, they should provide adequate
description of the employed models and their assumptions, as
well as a clear intuitive interpretation of the parameters of
S61 Trikalinos et al.: Meta-analysis of tests when there is a “gold standard” JGIMinterest in the models. At a minimum, we suggest that
systematic reviewers perform explorations in a qualitative,
graphical depiction of the data in the ROC space (see
Algorithm section). This will provide a qualitative summary
and highlight similarities and differences among the studies.
An example of such a graph is Figure 3, which illustrates the
diagnostic performance of early measurements of total serum
bilirubin (TSB) to identify post-discharge TSB above the 95
th
10- hour-specific percentile in newborns.
41
A WORKABLE ALGORITHM
We propose using the following three step algorithm for meta-
analyzing studies of medical test performance when there is a
“gold standard”. This algorithm should assist meta-analysts in
deciding whether a summary point, a summary line, or both
are helpful syntheses of the data. When reviewing the three
step algorithm, keep these points in mind:
& A summary point may be less helpful or interpretable
when the studies have different explicit thresholds for
positive tests, and when the estimates of sensitivity vary
widely along different specificities. In such cases, a
summary line may be more informative.
& A summary line may not be well estimated when the
sensitivities and specificities of the various studies show
little variability or when their estimated correlation
across studies is small. Further, if there is evidence that
the estimated correlation of sensitivity and specificity
across studies is positive (rather than negative, which
would be more typical), a “threshold effect” is not a
plausible explanation for the observed pattern across
studies. Rather, it is likely that an important covariate
has not been taken into account.
& In many applications, a reasonable case can be made for
summarizing studies both with a summary point and with
a summary line, as these provide alternative perspectives.
Step 1: Start by considering sensitivity
and specificity independently
This step is probably self explanatory; it encourages reviewers
to familiarize themselves with the pattern of study-level
sensitivities and specificities. It is very instructive to create
side-by-side forest plots of sensitivity and specificity in which
studies are ordered by either sensitivity or specificity. The point
of the graphical assessment is to obtain a visual impression of
the variability of sensitivity and specificity across studies, as
well as an impression of any relationship between sensitivity
and specificity across studies, particularly if such a relationship
is prominent (Fig. 1 and illustrative examples).
If a summary point is deemed a helpful summary of the data,
it is reasonable to first perform separate meta-analyses of
sensitivity and specificity. The differences in the point
estimates of summary sensitivity and specificity with univar-
iate (separate) versus bivariate (joint) meta-analyses is often
small. In an empirical exploration of 308 meta-analyses,
differences in the estimates of summary sensitivity and
specificity were rarely larger than 5 % (report under review,
Tufts Evidence-based Practice Center). The width of the
confidence intervals for the summary sensitivity and specificity
is also similar between univariate and bivariate analyses. This
suggests that practically, univariate and multivariate analyses
may yield comparable results. However, our recommendation
is to prefer reporting the results from the hierarchical
(multivariate) meta-analysis methods because of their better
theoretical motivation and because of their natural symmetry
with the multivariate methods that yield summary lines.
Step 2: Multivariate meta-analysis
(when each study reports a single threshold)
To obtain a summary point, meta-analysts should perform
bivariate meta-analyses (preferably using the exact binomial
likelihood).
Figure 3. Graphical presentation of studies reporting data at
multiple thresholds. Ability of early total serum bilirubin meas-
urements to identify postdischarge total serum bilirubin above the
95
th hour-specific percentile. Sensitivity and 100 percent minus
specificity pairs from the same study (obtained with different cut-
offs for the early total serum bilirubin measurement) are
connected with lines. These lines are reconstructed based on the
reported cut-offs, and are not perfect representations of the actual
ROC curves in each study (they show only a few thresholds that
could be extracted from the study). Studies listed on the left lightly
shaded area have a positive likelihood ratio of at least 10. Studies
listed on the top lightly shaded area have a negative likelihood
ratio of at most 0.1. Studies listed at the intersection of the gray
areas (darker gray polygon) have both a positive likelihood ratio
of at least 10 and a negative likelihood ratio of 0.1 or less.
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multivariate meta-analysis models. The interpretation of the
summary line should not automatically be that there are
“threshold effects”. This is most obvious when performing
meta-analyses with evidence of a positive correlation
between sensitivity and specificity, which cannot be
attributed to a “threshold effect”, as mentioned above.
If more than one threshold is reported per study and there
is no strong a priori rationale to review only results for a
specific threshold, meta-analysts should consider incorpo-
rating alternative thresholds into the appropriate analyses
discussed previously. Tentatively, we encourage both
qualitative analysis via graphs and quantitative analyses
via one of the multivariate methods mentioned above.
Step 3. Explore between-study heterogeneity
Other than accounting for the presence of a “threshold
effect”, the HSROC and bivariate models provide flexible
ways to test and explore between-study heterogeneity. The
HSROC model allows one to examine whether any
covariates (study characteristics) explain the observed het-
erogeneity in the accuracy and threshold parameters. One can
use the same set of covariates for both parameters, but this is
not mandatory, and should be judged for the application at
hand. On the other hand, bivariate models allow one to use
covariates to explain heterogeneity in sensitivity or specific-
ity or both; and again, covariates for each measure can be
different. Covariates that reduce the unexplained variability
across studies (heterogeneity) may represent important
characteristics that should be taken into account when
summarizing the studies, or they may represent spurious
associations. We refer to other texts for a discussion of the
premises and pitfalls of metaregressions.
24, 42 Factors
reflecting differences in patient populations and methods of
patient selection, methods of verification and interpretation of
results, clinical setting, and disease severity are common
sources of heterogeneity. Investigators are encouraged to use
multivariate models to explore heterogeneity, especially
when they have chosen these methods for combining studies.
Illustrations
We briefly demonstrate the above with two applied
examples. The first example on D-dimer assays for the
diagnosis of venous thromboembolism
15 shows heteroge-
neity which could be attributed to a “threshold effect” as
discussed by Lijmer et al..
43 The second example is from an
evidence report on the use of serial creatine kinase-MB
measurements for the diagnosis of acute cardiac ische-
mia,
16, 17 and shows heterogeneity for another reason.
D-dimers for diagnosis of venous thromboembolism. D-dimers
are fragments specific for fibrin degradation in plasma, and can
be used to diagnose venous thromboembolism. Figure 1
presents forest plots of the sensitivity and specificity and the
likelihood ratios for the D-dimer example.
43 Sensitivity and
specificity appear more heterogeneous than the likelihood ratios
(this is true by formal testing for heterogeneity). This may be
due to threshold variation in these studies (from 120 to 550 ng/
mL, when stated; Fig. 1), or due to other reasons.
43
Becauseoftheexplicitvariationinthethresholdsforstudies
of D-dimers, it is probably more helpful to summarize the
performance of the test using a HSROC, rather than to
provide summary sensitivities and specificities (Fig. 4a). (For
simplicity, we select the highest threshold from two studies
that report multiple ELISA thresholds.) This test has very
good diagnostic ability, and it appropriately focuses on
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Figure 4. HSROC for the ELISA-based D-dimer tests. (a) Hierarchical summary receiver-operator curve (HSROC) of the studies plotted in
Fig. 1a. (b) Calculated negative predictive value for the ELISA-based D-dimer test if the sensitivity and specificity are fixed at 80 % and
97 %, respectively, and prevalence of venous thromboembolism varies from 5 to 50 %.
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estimate “summary” negative (or positive) predictive values
for this test. As described previously, we can calulate them
based on the summary sensitivity and specificity estimates and
over a range of plausible values for the prevalence. Figure 4b
shows such an example using the summary sensitivity and
specificity of the 11 studies of Figure 4a.
Second example: Serial creatine kinase-MB measurements
for diagnosing acute cardiac ischemia. An evidence report
examined the ability of serial creatine kinase-MB (CK-MB)
measurements to diagnose acute cardiac ischemia in the
emergency department.
16, 17 Figure 5 shows the 14 eligible
studies along with how many hours after symptom onset the
last measurement was taken. It is evident that there is
between-study heterogeneity in the sensitivities, and that
sensitivity increases with longer time from symptom onset.
For illustrative purposes, we compare the summary
sensitivity and specificity of studies where the last
measurement was performed within three hours of
symptom onset versus greater than three hours from
symptom onset (Table 2). We used a bivariate multilevel
model with exact binomial likelihood. In the fixed effects
part of the model, we include a variable that codes
whether the last measurement was earlier than three hours
from symptom onset or not. We allow this variable to
have different effects on the summary sensitivity and on
the summary specificity. This is essentially a bivariate
meta-regression.
Note that properly specified bivariate meta-regressions
(or HSROC-based meta-regressions) can be used to
compare two or more medical tests. The specification of
the meta-regression models will be different when the
comparison is indirect (different medical tests are examined
in independent studies) or direct (the different medical tests
are applied in the same patients in each study).
OVERALL RECOMMENDATIONS
We summarize:
& Consider presenting a “summary point” when sensitivity
and specificity do not vary widely across studies, and
studies use the same explicit or “implicit threshold”.
– To obtain a summary sensitivity and specificity use the
theoretically motivated bivariate meta-analysis models.
– Back-calculate overall positive and negative predictive
values from summary estimates of sensitivity and
specificity, and for a plausible range of prevalence
values rather than meta-analyzing them directly.
– Back-calculate overall positive and negative likeli-
hood ratios from summary estimates of sensitivity
and specificity, rather than meta-analyzing them
directly.
Table 2. Meta-Regression-Based Comparison of Diagnostic
Performance
Meta-
analysis
metric
≤3 hours >3 hours p-Value for
the comparison
across subgroups
Summary
sensitivity
(percent)
80 (64 to 90) 96 (85 to 99) 0.036
Summary
specificity
(percent)
97 (94 to 98) 97 (95 to 99) 0.56
Results based on a bivariate meta-regression that effectively compared
the summary sensitivity and summary specificity according to the timing
of the last serial CK-MB measurement for diagnosis of acute cardiac
ischemia.Themeta-regressionisonavariablethattakesthevalue1ifthe
time from the onset of symptoms to testing was 3 hours or less, and the
value 0, when the respective time interval was more than 3 hours. The
bivariate meta-regression model allows for different effects of timing on
sensitivity and specificity. To facilitate interpretation, we present the
summary sensitivity and specificity in each subgroup, calculated from the
parameters of the meta-regression model, which also gave the p-values
for the effect of timing on test performance.
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Figure 5. Sensitivity 1–specificity plot for studies of serial CK-MB measurements. The left panel shows the sensitivity and specificity of 14
studies according to the timing of the last serial CK-MB measurement for diagnosis of acute cardiac ischemia. The numbers next to each
study point are the actual length of the time interval from symptom onset to last serial CK-MB measurement. Filled circles: at most 3 hours;
“x” marks: longer than 3 hours. The right panel plots the summary points and the 95 % confidence regions for the aforementioned
subgroups of studies (at most 3 hours: filled circles; longer than 3 hours—“ x”s). Estimates are based on a bivariate meta-regression using
the time interval as a predictor. The predictor has distinct effects for sensitivity and specificity. This is the same analysis as in Table 2.
S64 Trikalinos et al.: Meta-analysis of tests when there is a “gold standard” JGIM& If the sensitivity and specificity vary over a large range,
it may be more helpful to use a summary line, which
best describes the relationship of the average sensitivity
and specificity. The summary line approach is also most
helpful when different explicit thresholds are used
across studies. To obtain a summary line use multivar-
iate meta-analysis methods such as the HSROC model.
– Several SROC lines can be obtained based on
multivariate meta-analysis models, and they can
have different shapes.
– If there is evidence of a positive correlation, the
variability in the studies cannot be secondary to a
“threshold effect”; explore for missing important
covariates. Arguably, the summary line is a valid
description of how average sensitivity relates to
average specificity.
& If more than one threshold is reported per study, this has
to be taken into account in the quantitative analyses. We
encourage both qualitative analysis via graphs and
quantitative analyses via proper methods.
& One should explore the impact of study characteristics
on summary results in the context of the primary
methodology used to summarize studies using meta-
regression-based analyses or subgroup analyses.
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